Officials from the National Institute for Health and Care Excellence (Nice) have made a preliminary decision not to recommend covering the drug radium-223 dichloride (Xofigo) for use for men with prostate cancer that has spread to the bone. This latest draft guidance from Nice states that Bayer has not provided information on how Xofigo performs [...]
After a great deal of confusion and what turned out to be an error on my part I wish to let you know that the NICE (The U.K.’s National Institute for Health and Care Excellence) Guidance I shared on the blog on January 28, 2014 (http://advancedprostatecancer.net/?p=4360 ) about enzalutamide (Xtandi) was not accurate. In my [...]
Live in the UK and have advanced prostate cancer? If you do then be prepared to have economics over-ride your legitimate health concerns. The U.K.'s National Institute for Health and Care Excellence (NICE) makes no bones about what is more important, money or men’s health. NICE initially did not approve Zytiga, however when Johnson & [...]
The National Health Service cost regulators for England and Wales have recommended the use of Zytiga in the treatment of men with castrate resistant advanced prostate cancer. The National Institute for Health and Clinical Excellence (NICE) has published a final guidance endorsing Zytiga as an NHS treatment option for men with advanced, metastatic, castration resistant [...]